Geficure 250 – Gefitinib 250mg Tablets for Non-Small Cell Lung Cancer (NSCLC)

Geficure 250 is a prescription-based targeted anticancer medicine containing Gefitinib 250mg, indicated for the treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). It belongs to a class of medicines known as tyrosine kinase inhibitors (TKIs) that specifically target EGFR proteins responsible for the growth and multiplication of cancer cells.

Unlike conventional chemotherapy, Geficure 250 provides a targeted approach by blocking the signaling pathways that promote cancer cell growth. This helps slow disease progression, reduce tumor growth, and improve treatment outcomes in eligible patients. It is prescribed only after proper diagnostic evaluation and confirmation of EGFR mutation status.

Key Benefits of Geficure 250

• Effective treatment for EGFR mutation-positive non-small cell lung cancer (NSCLC)
• Helps block the growth and spread of cancer cells
• Targeted therapy with a precise mechanism of action
• Oral tablet for convenient daily administration
• Helps improve disease control and progression-free survival
• Used under the guidance of an experienced oncologist
• Supports personalized cancer treatment plans

Why Choose Geficure 250?

Geficure 250 offers a modern targeted therapy approach for patients with EGFR mutation-positive lung cancer. Compared with traditional chemotherapy, it specifically targets cancer cell signaling pathways, making it an important option in precision oncology. It is trusted by oncologists for its effectiveness, oral convenience, and role in improving disease management.

Directions for Use

• Take Geficure 250 exactly as prescribed by your oncologist.
• Swallow the tablet whole with water.
• It may be taken with or without food.
• Take the medicine at the same time each day.
• Do not stop treatment or change the dosage without consulting your doctor.

Important Safety Information

• Prescription-only anticancer medicine.
• Use only under the supervision of a qualified oncologist.
• Regular monitoring of liver function, lung health, and overall clinical condition may be required.
• Inform your healthcare provider about any pre-existing liver disease, lung disease, or other medical conditions.
• Do not self-medicate.
• Keep out of reach of children.